CC 49716/2024

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Verletzungs-Hauptverfahren:UPC CFI 145/2024

Verfahrensdetails: Status
—
Verfahrensart
Widerklage Nichtigkeit
Kategorie
Widerklage auf Nichtigkeit
Parteien: Kläger
Accord Healthcare S.L.U.
Accord Healthcare GmbH
Accord Healthcare B.V.
Accord Healthcare Italia Srl
Accord Healthcare AB
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Dr Reddy's Srl
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Vertreter: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)
Beklagte
Sanofi SA (successor of Sanofi Mature IP)
Sanofi Winthrop Industrie
Sanofi-Aventis GmbH
Sanofi Belgium
Sanofi-Aventis Deutschland GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Vertreter: Jules Fabre (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Richter: —
Technology: Pharmaceuticals · Oncology · Pharmaceutical & Medical
Sprache: —
Erste Entscheidung: 24. Jan. 2025

Entscheidungen

2025-01-24
Counterclaim for revocation
The Munich Local Division issued a procedural order in the infringement actions by Sanofi (and successor entities) against multiple generic pharmaceutical companies (Accord, STADA, Dr Reddy's, Zentiva) concerning EP 2 493 466 (UPC_CFI_145/2024 and related cases). The order concerns case management — identifying parties and representatives across the eight consolidated cases relating to counterclaims for revocation.
Rechtsfragen:Procedural case management across consolidated actionsCounterclaim for revocation in pharmaceutical patent infringement

Dokumente